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Abstract
Background: Matrix metalloproteinases (MMPs) are central to degradation of the extracellular
matrix and basement membrane during both normal and carcinogenic tissue remodeling. MT1-
MMP (MMP-14) and stromelysin-3 (MMP-11) are two members of the MMP family of proteolytic
enzymes that have been specifically implicated in breast cancer progression. Expressed in stromal
fibroblasts adjacent to epithelial tumour cells, the mechanism of MT1-MMP and MMP-11 induction
remains unknown.
Methods: To investigate possible mechanisms of induction, we examined the effects of a number
of plausible regulatory agents and treatments that may physiologically influence MMP expression
during tumour progression. Thus NIH3T3 and primary mouse embryonic fibroblasts (MEFs) were:
a) treated with the cytokines IL-1β, IL-2, IL-6, IL-8 and TGF-β for 3, 6, 12, 24, and 48 hours; b)
grown on collagens I, IV and V; c) treated with fibronectin, con-A and matrigel; and d) co-cultured
with a range of HBC (human breast cancer) cell lines of varied invasive and metastatic potential.
Results: Competitive quantitative RT-PCR indicated that MMP-11 expression was stimulated to a
level greater than 100%, by 48 hour treatments of IL-1β, IL-2, TGF-β, fibronectin and collagen V.
No other substantial changes in expression of MMP-11 or MT1-MMP in either tested fibroblast
culture, under any treatment conditions, were observed.
Conclusion: We have demonstrated significant MMP-11 stimulation in mouse fibroblasts using
cytokines, matrix constituents and HBC cell lines, and also some inhibition of MT1-MMP. Our data
suggest that the regulation of these genes in the complex stromal-epithelial interactions that occur
in human breast carcinoma, is influenced by several mechanisms.
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Integral to both normal and pathological tissue remode-
ling, the matrix metalloproteinase (MMP) family of prote-
olytic enzymes collectively degrades laminin, collagen,
gelatin, and other protein components of the extracellular
matrix [1,2]. MMP expression allows degradation of the
basement membrane, an event essential to the process of
tumour metastasis [3]. The induction of specific MMPs
such as MT1-MMP and MMP-11 have been shown to cor-
relate with tumour invasiveness and resultant metastasis
in several human cancers, including breast carcinoma [4-
7]. Thus, gene expression analysis of these two MMPs may
have clinical application in breast cancer diagnosis, man-
agement and therapy.
Little is known about the mechanisms underlying MT1-
MMP and MMP-11 induction. Previous studies have
revealed induction of MT1-MMP in human fibroblasts
grown on interstitial collagen (collagen I), which is abun-
dant around tumours and during wound healing [8]. Fur-
thermore, MMP-11 has been shown to be induced by
retinoic acid [9]. This study aimed to investigate possible
regulatory agents and treatments inducing MT1-MMP
and/or MMP-11 expression. Specifically, MMP induction
was measured in NIH3T3 and primary mouse embryonic
fibroblasts (MEFs) subjected to each of the following
potentially regulatory agents: collagen I, IV and V, conca-
navalin-A, fibronectin, and several exogenous cytokines.
As induction by such agents could be transitory, treatment
times were varied from 3, 6, 12, 24 and 48 hours, and
were immediately followed by RNA extraction.
As collagen I has been reported to induce MT1-MMP
expression, detection of such induction by quantitative
RT-PCR would provide an ideal basis for testing further
regulatory agents. Collagen IV and V appeared to be ideal
candidates for further analysis of MMP induction as they
are present in the basement membrane and would there-
fore be released specifically during early tumour invasion
and metastasis, which coincides with MT1-MMP and
MMP-11 expression in vivo. Type IV collagen has been
shown to mediate pro-MMP-2 activation in HT1080 cells,
a human fibrosarcoma cell line, without inducing either a
transcriptional modulation of MMP-2 or MT1-MMP
expression nor any alteration of MT1-MMP protein syn-
thesis or processing [10]. Concanavalin-A is a plant lectin
reported to stimulate activation of MMP-2 [11,12].
Fibronectin encourages cell adhesion and HT1080 cells
cultured on fibronectin have exhibited elevated levels of
MT1-MMP protein [13-15].
We investigated the potential role of the following
cytokines, interleukin (IL)-1β, IL-2, IL-6, IL-8 and trans-
forming growth factor (TGF)-β in MT1-MMP and MMP-
11 regulation. All of these cytokines are reportedly
released by neoplastic cells and are capable of affecting
transcription in fibroblasts [16-19]. IL-2 is also released by
tumour infiltrating lymphocytes (TILs) and IL-6 is
released by tumour associated macrophages (TAMs), TILs
and fibroblasts [16,20-22]. Moreover, MT1-MMP and
MMP-11 have both been reported to be induced in
human fibroblasts treated with conditioned medium
from MDA-MB-231, a highly invasive mammary tumour
cell line [23]. Thus, we investigated the induction of MT1-
MMP and MMP-11 in NIH3T3 and MEFs co-cultured with
a range of HBC (human breast cancer) cell lines of varied
invasive and metastatic potential. This allowed direct in
situ interaction of MMPs, growth factors and other poten-
tially regulatory agents between the fibroblasts and HBC
cells.
Methods
Cell lines
NIH3T3 culture was obtained from the ATCC, while MEF
cultures were constructed at the John Curtin School of
Medical Research, Australian National University. Briefly,
embryos were removed from 13-day pregnant mice. Fol-
lowing removal of the liver and head, the remaining tissue
was placed in PBS (1× pH 7.4, Sigma-Aldrich). Tissue was
homogenised using an 18 guage syringe (Terumo) in PBS,
plated in 25 cm2 tissue culture flasks (Costar) DMEM
(Dulbecco's modified Eagles medium) with 10% FCS
(Invitrogen) and allowed to attach for 6–12 hrs at 37°C,
5% CO2 prior to use. HBC cell lines were originally
obtained from the ATCC and maintained by The Lom-
bardi Cancer Center. ML-20 cells were derived from The
Lombardi Cancer Center MCF-7 cells by clonal selection
after transfection with a CMV-driven expression plasmid
encoding bacterial β-galactosidase.
Collagen coats and fibronectin treatment
Collagen coats and fibronectin treatments were prepared
on non-coated tissue culture plates as follows: prior to
seeding, triplicate sets of 2 ml 24 well plates (Costar) were
overlaid with 150 µl of collagen I, IV and V (Sigma, 1 mg/
ml) solutions. For the fibronectin treatments, 15 µg of
fibronectin (Promega), equivalent to 5 µg/cm2 of flask
area were added to each well in 2 ml 24 well plates (Cos-
tar). The wells were then incubated at 37°C for 1 hour to
allow the collagen coats and fibronectin to set in the wells.
Excess solution was aspirated from all wells before seed-
ing with 105 cells from either NIH3T3, or MEF cultures in
1 ml DMEM - 10% fetal calf serum (Invitrogen). Treated
cultures were then incubated at two time-points, 24 hours
and 48 hours at 37°C, 5% CO2, before undergoing RNA
extraction.
Con-A treatment
Non-coated 2 ml 24 well tissue culture plates (Costar)
were seeded with either NIH3T3 or MEF at 105 cells in 1Page 2 of 9
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fetal calf serum (Invitrogen). Treatments consisted of 25
µg Con-A added to the 1 ml of DMEM in each well.
Treated cultures were then incubated at two time-points,
24 hours and 48 hours at 37°C, 5% CO2, before undergo-
ing RNA extraction.
Cytokine treatments
2 ml 24 well plates (Costar) were seeded with 105 cells
from either NIH3T3 or primary mouse fibroblast cultures
(passage 5) in 1 mL Dulbecco's modified Eagles medium
(DMEM) - 10% fetal calf serum (Invitrogen). Cultures
were incubated at 37°C, 5% CO2 for 24 hours prior to
cytokine treatment, thus allowing complete attachment.
All treatments were separate and consisted of final solu-
tions of 100 units/ml IL-1β, IL-2, IL-6, 0.1 units/ml of IL-
8 and 1 ng/ml pan-TGF-β (Sigma-Aldrich) in cultures
grown in triplicate.
Co-cultures
30 mm 6 well plates (Costar) were seeded with 106 cells of
either NIH3T3 or MEFs (passage 5), which were each
allowed to attach overnight in 1 mL Dulbecco's modified
Eagles medium (DMEM) - 10% fetal calf serum (Invitro-
gen). The DMEM was then aspirated and 24 mm Tran-
swell Porous Cell Culture Inserts (Costar) were seeded
with 105 cells of either MDA-MB-231, MDA-MB-435,
MDA-MB-436, MCF-7s or ML-20 epithelial tumour cul-
tures in 2 ml of RPMI medium (Trace Biosystems) - 10%
fetal calf serum. Use of the porous inserts meant that co-
cultures were not in direct physical contact, but shared
growth media at all times. These HBC cultures exhibit dif-
ferent levels of invasive and metastatic potential (see
Table 1). Each co-culture then underwent 48 hour incuba-
tion at 37°C, 5% CO2, before RNA extraction.
RNA extraction and quantification
Total RNA was extracted from the fibroblasts using an
RNeasy Mini Kit (QIAGEN) as previously described [24].
Total RNA was then quantified at OD260 using a Quanta-
Gene spectrophotometer (The Australian Chromatogra-
phy Company, Sydney, NSW, Australia).
Oligonucleotide primers
All 3' primers were labeled with the TET dye phosphora-
midite and were commercially obtained (Applied Biosys-
tems, Brisbane, QLD, Australia). Oligonucleotides for the
target genes, MT1-MMP and MMP-11, were generated
using Amplify 2.1 analysis software in conjunction with
published cDNA sequences [6,25]. The oligonucleotide
sequences for the housekeeping gene 18S rRNA were sup-
plied by Ambion. All sequences utilised are outlined in
Table 2.
Constructing cDNA competitive templates
cDNA competitive templates for the target genes, MT1-
MMP and MMP-11 were made by PCR amplification
using purpose built 47-mer oligonucleotides as described
[26]. The 47-mers consisted of a 23 bp 5' primer comple-
mentary to target sequence either 28 bp, for MT1-MMP, or
20 bp, for MMP-11, further 5' than the remaining 24 bp
of the 47-mer, which consisted of the normal 5' primer
sequence for PCR. Hence, a PCR product generated from
these 5' 47-mers in combination with the normal 3' prim-
ers, produced fragments shorter than when using the nor-
mal 5' primer, as these deletions were left out during
Table 1: Invasive and metastatic potential of HBC cell lines [31].
Cell Line Estrogen Receptor Status Vimentin Expression Invasiveness
MDA-MB-231 - + +++
MDA-MB-435 - + ++
MDA-MB-436 - + ++
MCF-7 ++ - +
NCI-adr - + ++
MCF-7stv + - +
ML-20 + - +
Table 2: Oligonucleode primer sequences.
Gene 5' sequence 3' sequence Standard 
amplicon
Competitor sequence 
(standard 5' primer plus)
Competitor 
amplicon
MT1-MMP gACAgTACACCCTTTgATggTgAA gATCgTTAgAATgTTCCAggCCTA 197 bp CAgGCCCCAATATTggAggggAT 169 (-28 bp)
MMP-11 CCTTCCAggATgCTgAgggCTAT ATgACAgCATggTCgTTCCTACAA 330 bp TCTCTACTggAggTTTgATCCCgT 310 (-20 bp)
18s rRNA TCAAGAACgAAAgTCggAgg ggACATCTAAgggCATCACA 490 bp N/A N/APage 3 of 9
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5' and 3' ends of the competitive template remain comple-
mentary to normal primers and therefore undergo further
complementary-copying during additional PCR in a man-
ner identical to the target sequences, except that the miss-
ing nucleotide fragments remain absent. (Table 2)
Constructing mRNA competitive templates
The cDNA competitive templates generated by PCR with
the 47-mers described above were each ligated into
pGem-T Easy Vectors (Promega, Annandale, NSW, Aus-
tralia). JM109 (Promega) competent cells were then trans-
formed and grown overnight. Plasmid DNA was extracted
using a Magic Miniprep kit (Promega) and linearised by
nuclease digest. Mimic RNA was generated from the
"mimic" plasmids by transcription of the insert with T7
RNA polymerase (Promega). The post-transcription mix-
ture then underwent RQ1 DNase (Promega) digestion;
the remaining RNA was then purified using QIAGEN
RNeasy Minikit, RNA competitive template was then
resuspended in DEPC-treated H2O and stored at -70°C.
To ensure that amplification would not occur as a result of
residual DNA contamination, control samples were run in
triplicate without the reverse transcriptase thermal cycle.
No amplification products were visualised on resultant
agarose gels.
RT-PCR
Single tube, one step RT-PCR was performed as previously
described [24] for all samples using an ABI 480 thermal
cycler in 25 µl volume containing: 24 ng total RNA, 1–2
µl of RNA competitive template, being equivalent to 24 ng
of control total RNA, 200 mM dNTPs (Promega), 5× RT-
PCR buffer [300 mM Tris-HCl, pH 8.3; 2.5 mM DTT; 250
mM KCl; 0.5% Triton X-100 (Evergreen Scientific); 30 µm
EDTA; 7.5 mM MgCl2], 0.4 µM each primer, 1 unit Taq
polymerase (Perkin Elmer ABI), 1.2 units AMV reverse
transcriptase (Promega) and 900 ng tRNA (Boehringer
Mannheim)]. Thermal cycling was as follows: 30 mins
50°C (reverse transcription), then 2 mins 95°C, followed
by 35 cycles of 30 sec 95°C, 30 sec 65°C, 45 sec 72°C, fol-
lowed by a final incubation of 5 mins at 72°C.
GeneScan
3' primers for MT1-MMP, MMP-11 and 18S rRNA were
labeled with TET fluorescent dye, thus allowing RT-PCR
samples to be analysed by capillary electrophoresis using
a 310 Genetic Analyzer with GeneScan software (ABI) as
described previously [24]. Using laser technology to excite
the fluorescently labeled primers, samples were sized to
within one base pair and the amount of amplification
product of any given size, determined by fluorescence
peak area.
Ratio calculations
The GeneScan values for fluorescence peak area of the tar-
get gene transcripts and the control transcripts produced
the target:control ratio. All graphed values represent aver-
ages from triplicate samples and were adjusted to produce
a control value of 1.00. These target:control ratio values
were used to plot time series graphs of all combined data
for each gene. Data on the time series graphs was then
normalised to 18S rRNA expression, as measured in the
same respective cultures. The 0.5× control and 2.0× con-
trol are the resultant target:control ratios produced using
half and double the amount of total RNA used in the con-
trol sample, respectively.
Results
Induction treatments
MT1-MMP: 3, 6, 12 and 24 hour treatments
Competitive quantitative RT-PCR using capillary electro-
phoresis and GeneScan analysis revealed no substantial
changes in expression of MT1-MMP in either NIH3T3, or
MEF cultures under any treatment conditions carried out
over 3, 6, 12, and 24 hours (Tables 3 and 4). Although as
indicated in Table 3 there are some minor initial varia-
tions, when the normalised to 18S rRNA no substantial
changes are observed. The data presented are derived from
GeneScan values for fluorescence peak area of the target
gene transcripts and the control transcripts, thus produc-
ing the target:control ratio. All values represent averages
from samples run in triplicate and have been adjusted to
produce a control value of 1.00. Results for these time
periods display only minor variations and generally fall
between 0.5× control and 2.0× control expression levels.
MT1-MMP: 48 hour treatments
Induction
Initial analyses of the 48 hour IL-1β, IL-2 and fibronectin
treatments indicated consistently basal MT1-MMP expres-
sion levels (Table 5). Yet data for these treatments do indi-
cate induction when normalized to the unexpectedly low
level of 18S rRNA expression (Tables 7 and 8). However,
18S rRNA expression is monitored primarily to double
check for substantial anomalies in mRNA quantification
when positive results are found, rather than as a precise
means of normalization for results which appear consist-
ent. Furthermore, competitive RT-PCR of MT1-MMP may
be considered more accurate than non-competitive differ-
ential RT-PCR of 18S rRNA. Initial competitive RT-PCR of
MT1-MMP expression did produce consistently
unchanged results for these treatments, while expression
of 18S rRNA was found to display a relatively high level of
variation in this treatment group. Specifically, the level of
18S rRNA expression exhibited in the control was high,
therefore causing all other treatments to appear relatively
low, which in turn caused an artificial elevation of all
treatment data values during normalization. Hence, aPage 4 of 9
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Treatment Target:Control Ratio
3 Hours 6 Hours 12 Hours
MT1-MMP 
± SEM
MMP-11 ± 
SEM
18S rRNA ± 
SEM
MT1-MMP 
± SEM
MMP-11 ± 
SEM
18S rRNA ± 
SEM
MT1-MMP 
± SEM
MMP-11 ± 
SEM
18S rRNA ± 
SEM
Control 1.00 ± 0.08 1.00 ± 0.10 1.00 ± 0.04 1.00 ± 0.08 1.00 ± 0.10 1.00 ± 0.04 1.00 ± 0.08 1.00 ± 0.08 1.00 ± 0.02
TGF-β 0.49 ± 0.08 1.27 ± 0.06 1.27 ± 0.08 1.21 ± 0.09 0.82 ± 0.08 1.53 ± 0.10 - 0.74 ± 0.10 1.22 ± 0.04
IL-1β 0.63 ± 0.06 0.96 ± 0.09 0.89 ± 0.04 1.25 ± 0.04 0.69 ± 0.02 1.09 ± 0.04 1.86 ± 0.02 0.87 ± 0.04 0.98 ± 0.02
IL-2 0.61 ± 0.14 0.96 ± 0.13 0.89 ± 0.05 0.63 ± 0.04 0.74 ± 0.02 1.16 ± 0.03 1.39 ± 0.04 0.72 ± 0.06 0.87 ± 0.02
IL-6 0.55 ± 0.02 0.88 ± 0.02 0.89 ± 0.04 0.90 ± 0.02 0.78 ± 0.04 1.03 ± 0.02 1.77 ± 0.04 0.66 ± 0.02 1.33 ± 0.04
IL-8 0.42 ± 0.02 1.04 ± 0.02 0.87 ± 0.02 0.87 ± 0.02 0.69 ± 0.02 1.06 ± 0.02 1.97 ± 0.04 0.70 ± 0.02 0.89 ± 0.02
Table 4: MT1-MMP, MMP-11 and 18S rRNA Target:Control ratios for 3, 6 and 12 hour treatments of MEF cells.
Treatment Target:Control Ratio
3 Hours 6 Hours 12 Hours
MT1-MMP 
± SEM
MMP-11 ± 
SEM
18S rRNA ± 
SEM
MT1-MMP 
± SEM
MMP-11 ± 
SEM
18S rRNA ± 
SEM
MT1-MMP 
± SEM
MMP-11 ± 
SEM
18S rRNA ± 
SEM
Control 1.00 ± 0.06 1.00 ± 0.14 1.00 ± 0.04 1.00 ± 0.08 1.00 ± 0.10 1.00 ± 0.04 1.00 ± 0.08 1.00 ± 0.08 1.00 ± 0.02
TGF-β 0.52 ± 0.06 1.14 ± 0.08 1.35 ± 0.14 0.96 ± 0.08 1.14 ± 0.06 1.35 ± 0.16 0.80 ± 0.04 0.95 ± 0.08 1.34 ± 0.12
IL-1β 0.58 ± 0.06 0.74 ± 0.04 1.10 ± 0.10 1.12 ± 0.10 0.74 ± 0.06 1.24 ± 0.08 0.70 ± 0.04 0.75 ± 0.08 1.10 ± 0.08
IL-2 0.75 ± 0.14 0.90 ± 0.08 0.94 ± 0.06 0.59 ± 0.02 0.68 ± 0.05 0.95 ± 0.06 0.70 ± 0.04 0.75 ± 0.04 0.90 ± 0.02
IL-6 0.56 ± 0.02 0.90 ± 0.02 0.75 ± 0.06 0.85 ± 0.05 0.78 ± 0.08 1.15 ± 0.07 0.64 ± 0.02 0.74 ± 0.06 1.20 ± 0.02
IL-8 0.45 ± 0.03 0.96 ± 0.04 0.90 ± 0.02 0.75 ± 0.05 0.74 ± 0.05 1.00 ± 0.08 0.92 ± 0.04 0.76 ± 0.03 0.92 ± 0.02
Table 5: MT1-MMP, MMP-11 and 18S rRNA Target:Control ratios for 24 and 48 hour treatments of NIH3T3 cells.
Treatment Target:Control Ratio
24 Hour 48 Hour
MT1-MMP ± SEM MMP-11 ± SEM 18S rRNA ± SEM MT1-MMP ± SEM MMP-11 ± SEM 18S rRNA ± SEM
Control 1.00 ± 0.02 1.00 ± 0.02 1.00 ± 0.02 1.00 ± 0.08 1.00 ± 0.04 1.00 ± 0.05
Collagen I 1.00 ± 0.08 1.35 ± 0.10 0.90 ± 0.08 0.59 ± 0.06 1.27 ± 0.08 0.96 ± 0.04
Collagen IV 0.60 ± 0.06 0.68 ± 0.08 0.58 ± 0.06 0.35 ± 0.10 0.71 ± 0.10 0.60 ± 0.05
Collagen V 1.10 ± 0.10 1.65 ± 0.08 0.60 ± 0.06 0.96 ± .004 1.91 ± 0.08 0.56 ± 0.08
Con-A 1.00 ± 0.14 1.35 ± 0.12 0.78 ± 0.08 0.82 ± 0.10 1.41 ± 0.14 0.80 ± 0.02
TGF-β 0.95 ± 0.06 0.56 ± 0.06 0.60 ± 0.02 0.70 ± 0.12 1.67 ± 0.14 0.56 ± 0.10
Fibronectin 1.18 ± 0.12 0.72 ± 0.08 0.58 ± 0.02 0.95 ± 0.32 2.16 ± 0.24 0.52 ± 0.01
IL-1β 1.14 ± 0.02 0.78 ± 0.04 0.55 ± 0.02 1.09 ± 0.18 2.20 ± 0.24 0.48 ± 0.02
IL-2 1.33 ± 0.20 0.70 ± 0.08 0.50 ± 0.02 1.01 ± 0.02 1.57 ± 0.16 0.48 ± 0.02
IL-6 0.80 ± 0.04 0.74 ± 0.04 0.65 ± 0.02 0.75 ± 0.06 1.27 ± 0.08 0.68 ± 0.04Page 5 of 9
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MMP should not be discarded in favour of a single set of
unusually efficient differential RT-PCRs of 18S rRNA con-
trol samples. In our opinion, MT1-MMP expression
should be considered unaffected by IL-1β, IL-2 and
fibronectin treatments during this time schedule.
Inhibition
Results indicated substantial inhibition of MT1-MMP
expression by collagen I and collagen IV (Tables 5 and 6).
Expression values for these treatments remained well
below the 0.5× control expression level even after normal-
ization (Tables 7 and 8), despite this procedure raising the
values in a way that may have been to some degree artifi-
cial, as described above.
MMP-11: 3, 6, 12 and 24 hour treatments
Competitive quantitative RT-PCR using capillary electro-
phoresis and GeneScan analysis revealed no substantial
changes in expression of MMP-11 in either fibroblast cul-
ture under any treatment conditions carried out over 3, 6,
12 and 24 hours (Tables 3, 4 and 5). Results for these time
periods display only minor variations and generally fall
between 0.5× control and 2.0× control expression levels.
The use of an internal competitor to obtain increased spe-
cificity of target:template detection demonstrate data for
these time periods and is highly consistent. Such consist-
ency within groups of treatments carried out simultane-
ously (i.e: over an individual time schedule) further
suggests that the minor variations from control expression
levels which are present, may be due to amplification
anomalies rather than individual differences in gene
expression caused by specific treatments.
MMP-11: 48 hour treatment
At the 48 hour time point, MMP-11 expression appeared
to be stimulated at least 2 fold by IL-1β, TGF-β, fibronec-
tin and collagen V. Results indicate induction of MMP-11
by these agents independently of normalization to 18S
rRNA expression (Tables 7 and 8), which further
enhanced these expression values. IL-2 and IL-6 appeared
to produce a very mild induction of MMP-11 without nor-
malization to 18S rRNA, and only appeared to produce a
greater than 2 fold induction when undergoing such
normalization.
The data suggesting that MMP-11 expression is induced by
IL-1β, TGF-β, fibronectin and collagen V is highly persua-
sive given that these are the only data that demonstrate
considerable within-group variation. The standard devia-
tion for the 48 hour MMP-11 treatments was 47.6 while
the second greatest standard deviation value was 40.5 for
the 24 hour MMP-11 treatments. The average for all other
MMP-11 groups was 17.3. This increase over the average
variation is suggestive of differences in initial transcript
levels for individual treatments. Furthermore, the fact that
MT1-MMP expression levels (non-normalised) remained
consistently normal for this treatment, effectively acting as
an additional unregulated control, lends further credit to
the likelihood of specific regulation of MMP-11 after 48
hours of treatment. There are also mild trends toward up
regulation for the IL-2 and IL-6 treated samples.
Co-culture with HBC cell lines
Initial results demonstrate no induction or inhibition of
either MT1-MMP or MMP-11 in mouse fibroblasts by co-
culture with any of the HBC cell lines (Table 9). Results
are highly consistent and all treatment values fall between
0.5× control and 2.0× control. Moreover, minor variations
from control expression values observed for each co-cul-
ture are almost identical, between the two target genes.
Hence, the mild expression elevations seen with ML-20
and MDA-MB-436 for both MT1-MMP and MMP-11 are
in our opinion, artifactual.
Discussion
This study investigated the effects of a number of possible
regulatory agents on the expression of two members of the
MMP gene family for their role in human breast cancer
metastases. NIH3T3 and MEF cultures were treated with
cytokines, collagens, fibronectin, Con-A or matrigel, and
co-cultured with various HBC cell lines. The expression of
MT1-MMP and MMP-11 was then determined by compet-
itive RT-PCR using capillary electrophoresis and GeneS-
can technology. Only MMP-11 expression at 48 hours was
affected by treatment with IL-1β, TGF-β, fibronectin and
collagen V, in the tested fibroblasts cultures.
During tumour progression, the release of exogenous
cytokines by neoplastic cells and immunological cells
may cause a stimulatory effect on adjacent stromal fibrob-
lasts, resulting in matrix metalloproteinase (MMP) induc-
tion. Past studies indicate that some MMPs undergo
regulatory changes under the influence of cytokines
[18,27]. Another recent study reported the induction of
MMP-11 expression in primary cultured human fibrob-
lasts over a 48 hour period by IL-6, IGF-2, EGF and PDGR-
BB, but not by IL-1β or TNF-β [28]. Similar to the MT1-
MMP results presented in the present study, MT1-MMP
gene expression was reportedly not affected by insulin-
like growth factor (IGF)-2, epidermal growth factor (EGF),
platelet derived growth factor (PDGR)-BB, IL-6, TNF-β or
IL-1β [28]. Any influence exerted on MT1-MMP by
cytokines may be of particular interest because of its spe-
cific interaction with MMP-2, an MMP with a broad sub-
strate specificity. Hence, further analysis of candidate
stimulatory agents is required to elucidate possible mech-
anisms by which MT1-MMP expression is stimulated.Page 6 of 9
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effect from both collagen I and collagen IV on MT1-MMP
expression. Curiously, there is evidence suggesting that
collagen I actually stimulates MT1-MMP mRNA produc-
tion in fibroblasts and activates MMP-2 in a variety of cells
over a longer time period [8,29]. However, past studies on
rat smooth-muscle cell culture support findings that colla-
gen IV exhibits MT1-MMP inhibitory effects [12].
Despite reports of MDA-MB-231 conditioned media
inducing MT1-MMP expression [23] in human fibrob-
lasts, co-culture between MEFs and MDA-MB-231, did not
produce induction of either MT1-MMP or MMP-11 in this
study. This finding is likely to be due to species-specificity,
since mouse mammary stromal cells are not capable of
supporting normal human mammary reorganization in
vivo [30].
Although the co-cultures carried out here did not allow
cell-cell contact, the previous study also involved no cell-
cell contact, but rather treatment with pre-conditioned
media (application of isolated medium from one cell
population following in vitro expansion to an another iso-
lated cell population). Another possible explanation is
that the basal level of expression of MT1-MMP and MMP-
11 in cultured murine fibroblasts is elevated, thus render-
ing them refractory to exogenous regulatory agents. We
are currently investigating this possibility.
Table 6: MT1-MMP, MMP-11 and 18S rRNA Target:Control ratios for 24 and 48 hour treatments of MEF cells.
Treatment Target:Control Ratio
24 Hour 48 Hour
MT1-MMP ± SEM MMP-11 ± SEM 18S rRNA ± SEM MT1-MMP ± SEM MMP-11 ± SEM 18S rRNA ± SEM
Control 1.00 ± 0.02 1.00 ± 0.02 1.00 ± 0.02 1.00 ± 0.08 1.00 ± 0.04 1.00 ± 0.05
Collagen I 1.00 ± 0.08 1.38 ± 0.18 0.90 ± 0.04 0.84 ± 0.06 1.20 ± 0.10 0.94 ± 0.04
Collagen IV 1.10 ± 0.06 1.65 ± 0.08 0.58 ± 0.06 1.00 ± 0.08 1.45 ± 0.12 0.60 ± 0.05
Collagen V 1.04 ± 0.10 1.65 ± 0.08 0.60 ± 0.06 0.90 ± .004 1.80 ± 0.10 0.56 ± 0.02
Con-A 1.20 ± 0.14 0.66 ± 0.12 0.78 ± 0.08 0.95 ± 0.08 0.85 ± 0.10 0.80 ± 0.04
TGF-β 0.90 ± 0.06 0.56 ± 0.06 0.60 ± 0.02 0.84 ± 0.08 0.75 ± 0.05 0.64 ± 0.08
Fibronectin 1.07 ± 0.12 0.71 ± 0.08 0.58 ± 0.02 0.95 ± 0.32 0.95 ± 0.07 0.64 ± 0.04
IL-1β 1.34 ± 0.02 0.65 ± 0.04 0.55 ± 0.02 1.45 ± 0.16 1.86 ± 0.20 0.55 ± 0.03
IL-2 0.88 ± 0.20 0.66 ± 0.08 0.50 ± 0.02 0.96 ± 0.04 1.50 ± 0.10 0.56 ± 0.06
IL-6 1.03 ± 0.04 0.72 ± 0.04 0.65 ± 0.02 0.75 ± 0.06 1.15 ± 0.12 0.60 ± 0.02
Table 7: MT1-MMP and MMP-11 Target:Control ratios for 24 and 48 hour treatments normalised to 18S rRNA of NIH3T3 cells.
Treatment Target:Control Ratio
24 Hour 48 Hour
MT1-MMP ± SEM MMP-11 ± SEM MT1-MMP ± SEM MMP-11 ± SEM
Control 1.00 ± 0.02 1.00 ± 0.02 1.00 ± 0.08 1.00 ± 0.04
Collagen I 1.32 ± 0.08 1.35 ± 0.10 1.32 ± 0.08 1.27 ± 0.08
Collagen IV 1.26 ± 0.06 0.68 ± 0.08 1.26 ± 0.06 0.71 ± 0.10
Collagen V 1.60 ± 0.08 1.65 ± 0.08 3.55 ± 0.35 1.91 ± 0.08
Con-A 1.00 ± 0.02 1.35 ± 0.12 1.00 ± 0.02 1.41 ± 0.14
TGF-β 0.62 ± 0.04 0.56 ± 0.06 2.95 ± 0.25 1.67 ± 0.14
Fibronectin 0.75 ± 0.08 0.72 ± 0.08 4.65 ± 0.38 2.16 ± 0.24
IL-1β 0.72 ± 0.10 0.78 ± 0.04 4.32 ± 0.28 2.20 ± 0.24
IL-2 0.68 ± 0.08 0.70 ± 0.08 3.36 ± 0.30 1.57 ± 0.16
IL-6 0.70 ± 0.04 0.74 ± 0.04 1.90 ± 0.14 1.27 ± 0.08Page 7 of 9
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This study examined the effects of a number of regulatory
agents and treatments on the induction of MMP-11 and
MT1-MMP gene expression, factors that may influence
breast cancer tumour progression. Stimulation of MMP-
11 was demonstrated after treatments by both cytokines
(IL-1β, TGF-β) and by matrix constituents (collagen IV
and fibronectin), whilst MT1-MMP was inhibited by
matrix constituents (collagen I and fibronectin). The
results presented suggest that several mechanisms may be
involved in MMP-11 and MT1-MMP regulation as part of
the complex epithelial-stromal interactions that occur
within human breast carcinomas.
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Treatment Target:Control Ratio
24 Hour 48 Hour
MT1-MMP ± SEM MMP-11 ± SEM MT1-MMP ± SEM MMP-11 ± SEM
Control 1.00 ± 0.02 1.00 ± 0.02 1.00 ± 0.08 1.00 ± 0.04
Collagen I 1.28 ± 0.04 1.30 ± 0.6 1.28 ± 0.08 1.32 ± 0.04
Collagen IV 1.35 ± 0.05 0.76 ± 0.04 1.35 ± 0.05 0.68 ± 0.02
Collagen V 1.54 ± 0.02 1.45 ± 0.10 2.85 ± 0.35 1.68 ± 0.04
Con-A 1.00 ± 0.02 1.26 ± 0.06 1.00 ± 0.02 1.35 ± 0.05
TGF-β 0.75 ± 0.05 0.65 ± 0.03 2.60 ± 0.18 1.44 ± 0.12
Fibronectin 0.85 ± 0.05 0.90 ± 0.04 4.20 ± 0.26 1.86 ± 0.18
IL-1β 0.68 ± 0.08 0.70 ± 0.04 4.00 ± 0.20 1.95 ± 0.17
IL-2 0.74 ± 0.06 0.68 ± 0.02 3.14 ± 0.26 1.44 ± 0.10
IL-6 0.70 ± 0.02 0.80 ± 0.05 1.74 ± 0.12 1.15 ± 0.07
Table 9: MT1-MMP and MMP-11 Target:Control ratios for co-cultures with HBC cell lines normalised to 18S rRNA of NIH3T3 cells and 
MEF cells.
Treatment Target:Control Ratio
NIH3T3 MEF
MT1-MMP ± SEM MMP-11 ± SEM MT1-MMP ± SEM MMP-11 ± SEM
0.5 × Control 0.73 ± 0.08 0.40 ± 0.13 0.65 ± 0.10 0.38 ± 0.10
2.0 × Control 1.37 ± 0.18 1.48 ± 0.37 1.24 ± 0.08 1.55 ± 0.23
Control 1.00 ± 0.06 1.00 ± 0.09 1.00 ± 0.06 1.00 ± 0.09
MDA-MB-231 0.81 ± 0.08 0.71 ± 0.18 0.87 ± 0.09 0.65 ± 0.13
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MCF-7 0.82 ± 0.09 0.64 ± 0.31 0.86 ± 0.10 0.72 ± 0.26
MDA-MB-435 0.99 ± 0.11 0.65 ± 0.12 1.00 ± 0.13 0.62 ± 0.08
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